Physician profile
David Christopher Adams
NPI 1528042256
$3,218.17
in general payments reported to CMS, 2019-2025
23 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $299 · 2021: $299 · 2022: $421 · 2023: $440 · 2024: $251 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $1,045.60 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbvie INC. | $543.82 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $356.40 | 2019-2024 | |
| Pfizer INC. | $192.60 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $184.57 | 2019-2023 | Ilumya |
| Amgen INC. | $166.72 | 2020-2022 | |
| Leo Pharma INC. | $162.36 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $90.31 | 2022-2024 | Libtayo, Dupixent |
| Organogenesis INC. | $69.04 | 2023-2024 | Puraply |
| Genzyme Corporation | $54.29 | 2020-2025 | |
| Merz North America, INC. | $49.60 | 2024 | |
| Biofrontera INC. | $36.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.97 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $33.92 | 2022-2024 | |
| Celgene Corporation | $31.87 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.23 | 2020 | |
| Janssen Biotech, INC. | $27.34 | 2022 | |
| Ucb, INC. | $22.56 | 2024 | Bimzelx |
| Convatec INC. | $20.58 | 2024 | |
| Mallinckrodt Hospital Products INC. | $19.24 | 2024 | Acthar |
| Incyte Corporation | $16.28 | 2024 | Opzelura |
| Lilly USA, LLC | $14.61 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.